Advertisement

Related Videos

Deborah Collyar: What's In It for Patients?

Opening Session Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Mar
02
Today In Oncology
Advanced RCC After Immunotherapy Belzutifan Plus Lenvatinib or Cabozantinib
Adjuvant Pembrolizumab Plus Belzutifan in Patients With RCC at Increased Risk of Recurrence
Extended Endocrine Therapy in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer
Stereotactic vs Whole-Brain Radiation for Patients With Brain Metastases
Skin Fluorescent Imaging Shows High Sensitivity, Specificity for Discriminating Melanoma Lesions
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo